Sangramento durante a anticoagulação oral: alerta sobre um mal maior Sangrado durante la anticoagulación oral: alerta sobre un mal mayor Bleeding during oral anticoagulant therapy: warning against a greater hazard
FUNDAMENTO: Sangramento é uma das grandes preocupações em pacientes sob anticoagulação oral. OBJETIVO: Investigar causas determinantes do sangramento em usuários de anticoagulante oral. MÉTODOS: Foram acompanhados prospectivamente, por 48 ± 7,2 meses, 360 pacientes com fibrilação atrial (FA), todos...
Ausführliche Beschreibung
Autor*in: |
Paulo de Lara Lavítola [verfasserIn] Guilherme Sobreira Spina [verfasserIn] Roney Orismar Sampaio [verfasserIn] Flávio Tarasoutchi [verfasserIn] Max Grinberg [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch ; Portugiesisch |
Erschienen: |
2009 |
---|
Schlagwörter: |
---|
Übergeordnetes Werk: |
In: Arquivos Brasileiros de Cardiologia - Sociedade Brasileira de Cardiologia (SBC), 2004, 93(2009), 2, Seite 174-179 |
---|---|
Übergeordnetes Werk: |
volume:93 ; year:2009 ; number:2 ; pages:174-179 |
Links: |
Link aufrufen |
---|
DOI / URN: |
10.1590/S0066-782X2009000800017 |
---|
Katalog-ID: |
DOAJ027733734 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ027733734 | ||
003 | DE-627 | ||
005 | 20230307120523.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230226s2009 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1590/S0066-782X2009000800017 |2 doi | |
035 | |a (DE-627)DOAJ027733734 | ||
035 | |a (DE-599)DOAJca8f6ab1cec04d42ada7d4d21ba88d7d | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng |a por | ||
050 | 0 | |a RC666-701 | |
100 | 0 | |a Paulo de Lara Lavítola |e verfasserin |4 aut | |
245 | 1 | 0 | |a Sangramento durante a anticoagulação oral: alerta sobre um mal maior Sangrado durante la anticoagulación oral: alerta sobre un mal mayor Bleeding during oral anticoagulant therapy: warning against a greater hazard |
264 | 1 | |c 2009 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a FUNDAMENTO: Sangramento é uma das grandes preocupações em pacientes sob anticoagulação oral. OBJETIVO: Investigar causas determinantes do sangramento em usuários de anticoagulante oral. MÉTODOS: Foram acompanhados prospectivamente, por 48 ± 7,2 meses, 360 pacientes com fibrilação atrial (FA), todos em uso de anticoagulante oral (ACo) com INR-alvo de 2,0-3,5, avaliados em média a cada 30 dias. Os pacientes foram investigados quanto à presença de patologia associada que levasse a sangramento. RESULTADOS: Participaram deste estudo 338 pacientes. Desses, 210 (62,13%) eram do sexo feminino. A estenose mitral estava presente em 218 pacientes (64,4%), a prótese biológica mitral em 64 (18,9%) e a insuficiência da valva mitral em 56 (16,5%). O sangramento ocorreu em 65 pacientes (19,2%) e de forma grave em 7 (10%). Em 38/65 pacientes (58,5%), identificou-se nova doença associada, facilitadora do sangramento. Em 100% dos pacientes com sangramento na faixa terapêutica, foi encontrada doença associada, contra 49,05% de diagnóstico de doenças associadas naqueles com INR < 3,5 (p = 0,001). CONCLUSÃO: O diagnóstico de doença local associada ao sangramento foi frequente entre os medicados com anticoagulante oral (58,5%). Houve associação entre sangramento com INR na faixa terapêutica (INR 2,0-3,5) e diagnóstico de patologia predisponente a sangramento (p < 0,001). Em pacientes em uso de anticoagulante oral que apresentam sangramento, é mandatória a investigação da causa, sobretudo se a INR estiver na faixa terapêutica.<br<FUNDAMENTO: El sangrado es una de las grandes preocupaciones en pacientes bajo anticoagulación oral. OBJETIVO: Investigar causas determinantes del sangrado en usuarios de anticoagulante oral. MÉTODOS: Se realizó el seguimiento, prospectivamente, por 48 ± 7,2 meses, de 360 pacientes con fibrilación atrial (FA), todos en uso de anticoagulante oral (ACo) con INR-objetivo de 2,0-3,5, evaluados en promedio cada 30 días. Los pacientes se investigaron sobre la presencia de patología asociada que llevara al sangrado. RESULTADOS: Participaron en este estudio 338 pacientes. De ellos, 210 (62,13%) eran del sexo femenino. La estenosis mitral estaba presente en 218 pacientes (64,4%), la prótesis biológica mitral en 64 (18,9%) y la insuficiencia de la válvula mitral en 56 (16,5%). El sangrado ocurrió en 65 pacientes (19,2%) y de forma grave en 7 (10%). En 38/65 pacientes (58,5%), se identificó nueva enfermedad asociada, facilitadora del sangrado. En el 100% de los pacientes con sangrado en el intervalo terapéutico, se encontró enfermedad asociada, contra el 49,05% de diagnóstico de enfermedades asociadas en aquellos con INR < 3,5 (p = 0,001). CONCLUSIÓN: El diagnóstico de enfermedad local asociada al sangrado fue frecuente entre los medicados con anticoagulante oral (58,5%). Hubo asociación entre sangrado con INR en el intervalo terapéutico (INR 2,0-3,5) y diagnóstico de patología predisponente a sangrado (p < 0,001). En pacientes en uso de anticoagulante oral que presentan sangrado, es indispensable la investigación de la causa, sobre todo si la INR está en el intervalo terapéutico.<br<BACKGROUND: Bleeding is one of the main concerns in patients undergoing oral anticoagulation therapy. OBJECTIVE: To investigate the determinant causes of bleeding in patients undergoing oral anticoagulant therapy. METHODS: A total of 360 patients with atrial fibrillation (AF) undergoing oral anticoagulant (ACo) therapy, with a target INR of 2.0-3.5, were followed prospectively for a period of 48 ± 7.2 months. The patients were evaluated on average every 30 days and were investigated regarding the presence of associated pathology that could lead to bleeding. RESULTS: A total of 338 patients participated in the present study. Of these, 210 (62.13%) were females. Mitral stenosis was present in 218 patients (64.4%), a mitral biological prosthesis in 64 (18.9%) and mitral valve failure in 56 (16.5%) patients. Bleeding occurred in 65 patients (19.2%), being severe in 7 (10%) patients. In 38/65 patients, a new associated disease was identified, which facilitated bleeding. An associated disease was identified in 100% of the patients with bleeding within the therapeutic range, against 49.05% of associated disease diagnosis in those with an INR < 3.5 (p=0.001). CONCLUSION: The diagnosis of a local disease associated to the bleeding was frequent among those patients undergoing oral anticoagulant therapy (58.5%). There was an association between bleeding with an INR within the therapeutic range (INR=2.0-3.5) and the diagnosis of a pathology predisposing to bleeding (p<0.001). It is mandatory to investigate the cause of bleeding in patients undergoing oral anticoagulant therapy, especially if the INR is within the therapeutic range. | ||
650 | 4 | |a Hemorragia | |
650 | 4 | |a anticoagulantes | |
650 | 4 | |a estenosis de la válvula mitral | |
650 | 4 | |a fibrilación atrial | |
650 | 4 | |a estenose da valva mitral | |
650 | 4 | |a fibrilação atrial | |
650 | 4 | |a Hemorrhage | |
650 | 4 | |a anticoagulants | |
650 | 4 | |a mitral valve stenosis | |
650 | 4 | |a atrial fibrillation | |
653 | 0 | |a Diseases of the circulatory (Cardiovascular) system | |
700 | 0 | |a Guilherme Sobreira Spina |e verfasserin |4 aut | |
700 | 0 | |a Roney Orismar Sampaio |e verfasserin |4 aut | |
700 | 0 | |a Flávio Tarasoutchi |e verfasserin |4 aut | |
700 | 0 | |a Max Grinberg |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t Arquivos Brasileiros de Cardiologia |d Sociedade Brasileira de Cardiologia (SBC), 2004 |g 93(2009), 2, Seite 174-179 |w (DE-627)320623572 |w (DE-600)2023015-1 |x 16784170 |7 nnns |
773 | 1 | 8 | |g volume:93 |g year:2009 |g number:2 |g pages:174-179 |
856 | 4 | 0 | |u https://doi.org/10.1590/S0066-782X2009000800017 |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/ca8f6ab1cec04d42ada7d4d21ba88d7d |z kostenfrei |
856 | 4 | 0 | |u http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2009000800017 |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/0066-782X |y Journal toc |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/1678-4170 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_DOAJ | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |d 93 |j 2009 |e 2 |h 174-179 |
author_variant |
p d l l pdll g s s gss r o s ros f t ft m g mg |
---|---|
matchkey_str |
article:16784170:2009----::agaetdrneatcauaoaaetsbemamiragaouatlatcauaioaaetsbenamyrleiguigrln |
hierarchy_sort_str |
2009 |
callnumber-subject-code |
RC |
publishDate |
2009 |
allfields |
10.1590/S0066-782X2009000800017 doi (DE-627)DOAJ027733734 (DE-599)DOAJca8f6ab1cec04d42ada7d4d21ba88d7d DE-627 ger DE-627 rakwb eng por RC666-701 Paulo de Lara Lavítola verfasserin aut Sangramento durante a anticoagulação oral: alerta sobre um mal maior Sangrado durante la anticoagulación oral: alerta sobre un mal mayor Bleeding during oral anticoagulant therapy: warning against a greater hazard 2009 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier FUNDAMENTO: Sangramento é uma das grandes preocupações em pacientes sob anticoagulação oral. OBJETIVO: Investigar causas determinantes do sangramento em usuários de anticoagulante oral. MÉTODOS: Foram acompanhados prospectivamente, por 48 ± 7,2 meses, 360 pacientes com fibrilação atrial (FA), todos em uso de anticoagulante oral (ACo) com INR-alvo de 2,0-3,5, avaliados em média a cada 30 dias. Os pacientes foram investigados quanto à presença de patologia associada que levasse a sangramento. RESULTADOS: Participaram deste estudo 338 pacientes. Desses, 210 (62,13%) eram do sexo feminino. A estenose mitral estava presente em 218 pacientes (64,4%), a prótese biológica mitral em 64 (18,9%) e a insuficiência da valva mitral em 56 (16,5%). O sangramento ocorreu em 65 pacientes (19,2%) e de forma grave em 7 (10%). Em 38/65 pacientes (58,5%), identificou-se nova doença associada, facilitadora do sangramento. Em 100% dos pacientes com sangramento na faixa terapêutica, foi encontrada doença associada, contra 49,05% de diagnóstico de doenças associadas naqueles com INR < 3,5 (p = 0,001). CONCLUSÃO: O diagnóstico de doença local associada ao sangramento foi frequente entre os medicados com anticoagulante oral (58,5%). Houve associação entre sangramento com INR na faixa terapêutica (INR 2,0-3,5) e diagnóstico de patologia predisponente a sangramento (p < 0,001). Em pacientes em uso de anticoagulante oral que apresentam sangramento, é mandatória a investigação da causa, sobretudo se a INR estiver na faixa terapêutica.<br<FUNDAMENTO: El sangrado es una de las grandes preocupaciones en pacientes bajo anticoagulación oral. OBJETIVO: Investigar causas determinantes del sangrado en usuarios de anticoagulante oral. MÉTODOS: Se realizó el seguimiento, prospectivamente, por 48 ± 7,2 meses, de 360 pacientes con fibrilación atrial (FA), todos en uso de anticoagulante oral (ACo) con INR-objetivo de 2,0-3,5, evaluados en promedio cada 30 días. Los pacientes se investigaron sobre la presencia de patología asociada que llevara al sangrado. RESULTADOS: Participaron en este estudio 338 pacientes. De ellos, 210 (62,13%) eran del sexo femenino. La estenosis mitral estaba presente en 218 pacientes (64,4%), la prótesis biológica mitral en 64 (18,9%) y la insuficiencia de la válvula mitral en 56 (16,5%). El sangrado ocurrió en 65 pacientes (19,2%) y de forma grave en 7 (10%). En 38/65 pacientes (58,5%), se identificó nueva enfermedad asociada, facilitadora del sangrado. En el 100% de los pacientes con sangrado en el intervalo terapéutico, se encontró enfermedad asociada, contra el 49,05% de diagnóstico de enfermedades asociadas en aquellos con INR < 3,5 (p = 0,001). CONCLUSIÓN: El diagnóstico de enfermedad local asociada al sangrado fue frecuente entre los medicados con anticoagulante oral (58,5%). Hubo asociación entre sangrado con INR en el intervalo terapéutico (INR 2,0-3,5) y diagnóstico de patología predisponente a sangrado (p < 0,001). En pacientes en uso de anticoagulante oral que presentan sangrado, es indispensable la investigación de la causa, sobre todo si la INR está en el intervalo terapéutico.<br<BACKGROUND: Bleeding is one of the main concerns in patients undergoing oral anticoagulation therapy. OBJECTIVE: To investigate the determinant causes of bleeding in patients undergoing oral anticoagulant therapy. METHODS: A total of 360 patients with atrial fibrillation (AF) undergoing oral anticoagulant (ACo) therapy, with a target INR of 2.0-3.5, were followed prospectively for a period of 48 ± 7.2 months. The patients were evaluated on average every 30 days and were investigated regarding the presence of associated pathology that could lead to bleeding. RESULTS: A total of 338 patients participated in the present study. Of these, 210 (62.13%) were females. Mitral stenosis was present in 218 patients (64.4%), a mitral biological prosthesis in 64 (18.9%) and mitral valve failure in 56 (16.5%) patients. Bleeding occurred in 65 patients (19.2%), being severe in 7 (10%) patients. In 38/65 patients, a new associated disease was identified, which facilitated bleeding. An associated disease was identified in 100% of the patients with bleeding within the therapeutic range, against 49.05% of associated disease diagnosis in those with an INR < 3.5 (p=0.001). CONCLUSION: The diagnosis of a local disease associated to the bleeding was frequent among those patients undergoing oral anticoagulant therapy (58.5%). There was an association between bleeding with an INR within the therapeutic range (INR=2.0-3.5) and the diagnosis of a pathology predisposing to bleeding (p<0.001). It is mandatory to investigate the cause of bleeding in patients undergoing oral anticoagulant therapy, especially if the INR is within the therapeutic range. Hemorragia anticoagulantes estenosis de la válvula mitral fibrilación atrial estenose da valva mitral fibrilação atrial Hemorrhage anticoagulants mitral valve stenosis atrial fibrillation Diseases of the circulatory (Cardiovascular) system Guilherme Sobreira Spina verfasserin aut Roney Orismar Sampaio verfasserin aut Flávio Tarasoutchi verfasserin aut Max Grinberg verfasserin aut In Arquivos Brasileiros de Cardiologia Sociedade Brasileira de Cardiologia (SBC), 2004 93(2009), 2, Seite 174-179 (DE-627)320623572 (DE-600)2023015-1 16784170 nnns volume:93 year:2009 number:2 pages:174-179 https://doi.org/10.1590/S0066-782X2009000800017 kostenfrei https://doaj.org/article/ca8f6ab1cec04d42ada7d4d21ba88d7d kostenfrei http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2009000800017 kostenfrei https://doaj.org/toc/0066-782X Journal toc kostenfrei https://doaj.org/toc/1678-4170 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 93 2009 2 174-179 |
spelling |
10.1590/S0066-782X2009000800017 doi (DE-627)DOAJ027733734 (DE-599)DOAJca8f6ab1cec04d42ada7d4d21ba88d7d DE-627 ger DE-627 rakwb eng por RC666-701 Paulo de Lara Lavítola verfasserin aut Sangramento durante a anticoagulação oral: alerta sobre um mal maior Sangrado durante la anticoagulación oral: alerta sobre un mal mayor Bleeding during oral anticoagulant therapy: warning against a greater hazard 2009 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier FUNDAMENTO: Sangramento é uma das grandes preocupações em pacientes sob anticoagulação oral. OBJETIVO: Investigar causas determinantes do sangramento em usuários de anticoagulante oral. MÉTODOS: Foram acompanhados prospectivamente, por 48 ± 7,2 meses, 360 pacientes com fibrilação atrial (FA), todos em uso de anticoagulante oral (ACo) com INR-alvo de 2,0-3,5, avaliados em média a cada 30 dias. Os pacientes foram investigados quanto à presença de patologia associada que levasse a sangramento. RESULTADOS: Participaram deste estudo 338 pacientes. Desses, 210 (62,13%) eram do sexo feminino. A estenose mitral estava presente em 218 pacientes (64,4%), a prótese biológica mitral em 64 (18,9%) e a insuficiência da valva mitral em 56 (16,5%). O sangramento ocorreu em 65 pacientes (19,2%) e de forma grave em 7 (10%). Em 38/65 pacientes (58,5%), identificou-se nova doença associada, facilitadora do sangramento. Em 100% dos pacientes com sangramento na faixa terapêutica, foi encontrada doença associada, contra 49,05% de diagnóstico de doenças associadas naqueles com INR < 3,5 (p = 0,001). CONCLUSÃO: O diagnóstico de doença local associada ao sangramento foi frequente entre os medicados com anticoagulante oral (58,5%). Houve associação entre sangramento com INR na faixa terapêutica (INR 2,0-3,5) e diagnóstico de patologia predisponente a sangramento (p < 0,001). Em pacientes em uso de anticoagulante oral que apresentam sangramento, é mandatória a investigação da causa, sobretudo se a INR estiver na faixa terapêutica.<br<FUNDAMENTO: El sangrado es una de las grandes preocupaciones en pacientes bajo anticoagulación oral. OBJETIVO: Investigar causas determinantes del sangrado en usuarios de anticoagulante oral. MÉTODOS: Se realizó el seguimiento, prospectivamente, por 48 ± 7,2 meses, de 360 pacientes con fibrilación atrial (FA), todos en uso de anticoagulante oral (ACo) con INR-objetivo de 2,0-3,5, evaluados en promedio cada 30 días. Los pacientes se investigaron sobre la presencia de patología asociada que llevara al sangrado. RESULTADOS: Participaron en este estudio 338 pacientes. De ellos, 210 (62,13%) eran del sexo femenino. La estenosis mitral estaba presente en 218 pacientes (64,4%), la prótesis biológica mitral en 64 (18,9%) y la insuficiencia de la válvula mitral en 56 (16,5%). El sangrado ocurrió en 65 pacientes (19,2%) y de forma grave en 7 (10%). En 38/65 pacientes (58,5%), se identificó nueva enfermedad asociada, facilitadora del sangrado. En el 100% de los pacientes con sangrado en el intervalo terapéutico, se encontró enfermedad asociada, contra el 49,05% de diagnóstico de enfermedades asociadas en aquellos con INR < 3,5 (p = 0,001). CONCLUSIÓN: El diagnóstico de enfermedad local asociada al sangrado fue frecuente entre los medicados con anticoagulante oral (58,5%). Hubo asociación entre sangrado con INR en el intervalo terapéutico (INR 2,0-3,5) y diagnóstico de patología predisponente a sangrado (p < 0,001). En pacientes en uso de anticoagulante oral que presentan sangrado, es indispensable la investigación de la causa, sobre todo si la INR está en el intervalo terapéutico.<br<BACKGROUND: Bleeding is one of the main concerns in patients undergoing oral anticoagulation therapy. OBJECTIVE: To investigate the determinant causes of bleeding in patients undergoing oral anticoagulant therapy. METHODS: A total of 360 patients with atrial fibrillation (AF) undergoing oral anticoagulant (ACo) therapy, with a target INR of 2.0-3.5, were followed prospectively for a period of 48 ± 7.2 months. The patients were evaluated on average every 30 days and were investigated regarding the presence of associated pathology that could lead to bleeding. RESULTS: A total of 338 patients participated in the present study. Of these, 210 (62.13%) were females. Mitral stenosis was present in 218 patients (64.4%), a mitral biological prosthesis in 64 (18.9%) and mitral valve failure in 56 (16.5%) patients. Bleeding occurred in 65 patients (19.2%), being severe in 7 (10%) patients. In 38/65 patients, a new associated disease was identified, which facilitated bleeding. An associated disease was identified in 100% of the patients with bleeding within the therapeutic range, against 49.05% of associated disease diagnosis in those with an INR < 3.5 (p=0.001). CONCLUSION: The diagnosis of a local disease associated to the bleeding was frequent among those patients undergoing oral anticoagulant therapy (58.5%). There was an association between bleeding with an INR within the therapeutic range (INR=2.0-3.5) and the diagnosis of a pathology predisposing to bleeding (p<0.001). It is mandatory to investigate the cause of bleeding in patients undergoing oral anticoagulant therapy, especially if the INR is within the therapeutic range. Hemorragia anticoagulantes estenosis de la válvula mitral fibrilación atrial estenose da valva mitral fibrilação atrial Hemorrhage anticoagulants mitral valve stenosis atrial fibrillation Diseases of the circulatory (Cardiovascular) system Guilherme Sobreira Spina verfasserin aut Roney Orismar Sampaio verfasserin aut Flávio Tarasoutchi verfasserin aut Max Grinberg verfasserin aut In Arquivos Brasileiros de Cardiologia Sociedade Brasileira de Cardiologia (SBC), 2004 93(2009), 2, Seite 174-179 (DE-627)320623572 (DE-600)2023015-1 16784170 nnns volume:93 year:2009 number:2 pages:174-179 https://doi.org/10.1590/S0066-782X2009000800017 kostenfrei https://doaj.org/article/ca8f6ab1cec04d42ada7d4d21ba88d7d kostenfrei http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2009000800017 kostenfrei https://doaj.org/toc/0066-782X Journal toc kostenfrei https://doaj.org/toc/1678-4170 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 93 2009 2 174-179 |
allfields_unstemmed |
10.1590/S0066-782X2009000800017 doi (DE-627)DOAJ027733734 (DE-599)DOAJca8f6ab1cec04d42ada7d4d21ba88d7d DE-627 ger DE-627 rakwb eng por RC666-701 Paulo de Lara Lavítola verfasserin aut Sangramento durante a anticoagulação oral: alerta sobre um mal maior Sangrado durante la anticoagulación oral: alerta sobre un mal mayor Bleeding during oral anticoagulant therapy: warning against a greater hazard 2009 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier FUNDAMENTO: Sangramento é uma das grandes preocupações em pacientes sob anticoagulação oral. OBJETIVO: Investigar causas determinantes do sangramento em usuários de anticoagulante oral. MÉTODOS: Foram acompanhados prospectivamente, por 48 ± 7,2 meses, 360 pacientes com fibrilação atrial (FA), todos em uso de anticoagulante oral (ACo) com INR-alvo de 2,0-3,5, avaliados em média a cada 30 dias. Os pacientes foram investigados quanto à presença de patologia associada que levasse a sangramento. RESULTADOS: Participaram deste estudo 338 pacientes. Desses, 210 (62,13%) eram do sexo feminino. A estenose mitral estava presente em 218 pacientes (64,4%), a prótese biológica mitral em 64 (18,9%) e a insuficiência da valva mitral em 56 (16,5%). O sangramento ocorreu em 65 pacientes (19,2%) e de forma grave em 7 (10%). Em 38/65 pacientes (58,5%), identificou-se nova doença associada, facilitadora do sangramento. Em 100% dos pacientes com sangramento na faixa terapêutica, foi encontrada doença associada, contra 49,05% de diagnóstico de doenças associadas naqueles com INR < 3,5 (p = 0,001). CONCLUSÃO: O diagnóstico de doença local associada ao sangramento foi frequente entre os medicados com anticoagulante oral (58,5%). Houve associação entre sangramento com INR na faixa terapêutica (INR 2,0-3,5) e diagnóstico de patologia predisponente a sangramento (p < 0,001). Em pacientes em uso de anticoagulante oral que apresentam sangramento, é mandatória a investigação da causa, sobretudo se a INR estiver na faixa terapêutica.<br<FUNDAMENTO: El sangrado es una de las grandes preocupaciones en pacientes bajo anticoagulación oral. OBJETIVO: Investigar causas determinantes del sangrado en usuarios de anticoagulante oral. MÉTODOS: Se realizó el seguimiento, prospectivamente, por 48 ± 7,2 meses, de 360 pacientes con fibrilación atrial (FA), todos en uso de anticoagulante oral (ACo) con INR-objetivo de 2,0-3,5, evaluados en promedio cada 30 días. Los pacientes se investigaron sobre la presencia de patología asociada que llevara al sangrado. RESULTADOS: Participaron en este estudio 338 pacientes. De ellos, 210 (62,13%) eran del sexo femenino. La estenosis mitral estaba presente en 218 pacientes (64,4%), la prótesis biológica mitral en 64 (18,9%) y la insuficiencia de la válvula mitral en 56 (16,5%). El sangrado ocurrió en 65 pacientes (19,2%) y de forma grave en 7 (10%). En 38/65 pacientes (58,5%), se identificó nueva enfermedad asociada, facilitadora del sangrado. En el 100% de los pacientes con sangrado en el intervalo terapéutico, se encontró enfermedad asociada, contra el 49,05% de diagnóstico de enfermedades asociadas en aquellos con INR < 3,5 (p = 0,001). CONCLUSIÓN: El diagnóstico de enfermedad local asociada al sangrado fue frecuente entre los medicados con anticoagulante oral (58,5%). Hubo asociación entre sangrado con INR en el intervalo terapéutico (INR 2,0-3,5) y diagnóstico de patología predisponente a sangrado (p < 0,001). En pacientes en uso de anticoagulante oral que presentan sangrado, es indispensable la investigación de la causa, sobre todo si la INR está en el intervalo terapéutico.<br<BACKGROUND: Bleeding is one of the main concerns in patients undergoing oral anticoagulation therapy. OBJECTIVE: To investigate the determinant causes of bleeding in patients undergoing oral anticoagulant therapy. METHODS: A total of 360 patients with atrial fibrillation (AF) undergoing oral anticoagulant (ACo) therapy, with a target INR of 2.0-3.5, were followed prospectively for a period of 48 ± 7.2 months. The patients were evaluated on average every 30 days and were investigated regarding the presence of associated pathology that could lead to bleeding. RESULTS: A total of 338 patients participated in the present study. Of these, 210 (62.13%) were females. Mitral stenosis was present in 218 patients (64.4%), a mitral biological prosthesis in 64 (18.9%) and mitral valve failure in 56 (16.5%) patients. Bleeding occurred in 65 patients (19.2%), being severe in 7 (10%) patients. In 38/65 patients, a new associated disease was identified, which facilitated bleeding. An associated disease was identified in 100% of the patients with bleeding within the therapeutic range, against 49.05% of associated disease diagnosis in those with an INR < 3.5 (p=0.001). CONCLUSION: The diagnosis of a local disease associated to the bleeding was frequent among those patients undergoing oral anticoagulant therapy (58.5%). There was an association between bleeding with an INR within the therapeutic range (INR=2.0-3.5) and the diagnosis of a pathology predisposing to bleeding (p<0.001). It is mandatory to investigate the cause of bleeding in patients undergoing oral anticoagulant therapy, especially if the INR is within the therapeutic range. Hemorragia anticoagulantes estenosis de la válvula mitral fibrilación atrial estenose da valva mitral fibrilação atrial Hemorrhage anticoagulants mitral valve stenosis atrial fibrillation Diseases of the circulatory (Cardiovascular) system Guilherme Sobreira Spina verfasserin aut Roney Orismar Sampaio verfasserin aut Flávio Tarasoutchi verfasserin aut Max Grinberg verfasserin aut In Arquivos Brasileiros de Cardiologia Sociedade Brasileira de Cardiologia (SBC), 2004 93(2009), 2, Seite 174-179 (DE-627)320623572 (DE-600)2023015-1 16784170 nnns volume:93 year:2009 number:2 pages:174-179 https://doi.org/10.1590/S0066-782X2009000800017 kostenfrei https://doaj.org/article/ca8f6ab1cec04d42ada7d4d21ba88d7d kostenfrei http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2009000800017 kostenfrei https://doaj.org/toc/0066-782X Journal toc kostenfrei https://doaj.org/toc/1678-4170 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 93 2009 2 174-179 |
allfieldsGer |
10.1590/S0066-782X2009000800017 doi (DE-627)DOAJ027733734 (DE-599)DOAJca8f6ab1cec04d42ada7d4d21ba88d7d DE-627 ger DE-627 rakwb eng por RC666-701 Paulo de Lara Lavítola verfasserin aut Sangramento durante a anticoagulação oral: alerta sobre um mal maior Sangrado durante la anticoagulación oral: alerta sobre un mal mayor Bleeding during oral anticoagulant therapy: warning against a greater hazard 2009 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier FUNDAMENTO: Sangramento é uma das grandes preocupações em pacientes sob anticoagulação oral. OBJETIVO: Investigar causas determinantes do sangramento em usuários de anticoagulante oral. MÉTODOS: Foram acompanhados prospectivamente, por 48 ± 7,2 meses, 360 pacientes com fibrilação atrial (FA), todos em uso de anticoagulante oral (ACo) com INR-alvo de 2,0-3,5, avaliados em média a cada 30 dias. Os pacientes foram investigados quanto à presença de patologia associada que levasse a sangramento. RESULTADOS: Participaram deste estudo 338 pacientes. Desses, 210 (62,13%) eram do sexo feminino. A estenose mitral estava presente em 218 pacientes (64,4%), a prótese biológica mitral em 64 (18,9%) e a insuficiência da valva mitral em 56 (16,5%). O sangramento ocorreu em 65 pacientes (19,2%) e de forma grave em 7 (10%). Em 38/65 pacientes (58,5%), identificou-se nova doença associada, facilitadora do sangramento. Em 100% dos pacientes com sangramento na faixa terapêutica, foi encontrada doença associada, contra 49,05% de diagnóstico de doenças associadas naqueles com INR < 3,5 (p = 0,001). CONCLUSÃO: O diagnóstico de doença local associada ao sangramento foi frequente entre os medicados com anticoagulante oral (58,5%). Houve associação entre sangramento com INR na faixa terapêutica (INR 2,0-3,5) e diagnóstico de patologia predisponente a sangramento (p < 0,001). Em pacientes em uso de anticoagulante oral que apresentam sangramento, é mandatória a investigação da causa, sobretudo se a INR estiver na faixa terapêutica.<br<FUNDAMENTO: El sangrado es una de las grandes preocupaciones en pacientes bajo anticoagulación oral. OBJETIVO: Investigar causas determinantes del sangrado en usuarios de anticoagulante oral. MÉTODOS: Se realizó el seguimiento, prospectivamente, por 48 ± 7,2 meses, de 360 pacientes con fibrilación atrial (FA), todos en uso de anticoagulante oral (ACo) con INR-objetivo de 2,0-3,5, evaluados en promedio cada 30 días. Los pacientes se investigaron sobre la presencia de patología asociada que llevara al sangrado. RESULTADOS: Participaron en este estudio 338 pacientes. De ellos, 210 (62,13%) eran del sexo femenino. La estenosis mitral estaba presente en 218 pacientes (64,4%), la prótesis biológica mitral en 64 (18,9%) y la insuficiencia de la válvula mitral en 56 (16,5%). El sangrado ocurrió en 65 pacientes (19,2%) y de forma grave en 7 (10%). En 38/65 pacientes (58,5%), se identificó nueva enfermedad asociada, facilitadora del sangrado. En el 100% de los pacientes con sangrado en el intervalo terapéutico, se encontró enfermedad asociada, contra el 49,05% de diagnóstico de enfermedades asociadas en aquellos con INR < 3,5 (p = 0,001). CONCLUSIÓN: El diagnóstico de enfermedad local asociada al sangrado fue frecuente entre los medicados con anticoagulante oral (58,5%). Hubo asociación entre sangrado con INR en el intervalo terapéutico (INR 2,0-3,5) y diagnóstico de patología predisponente a sangrado (p < 0,001). En pacientes en uso de anticoagulante oral que presentan sangrado, es indispensable la investigación de la causa, sobre todo si la INR está en el intervalo terapéutico.<br<BACKGROUND: Bleeding is one of the main concerns in patients undergoing oral anticoagulation therapy. OBJECTIVE: To investigate the determinant causes of bleeding in patients undergoing oral anticoagulant therapy. METHODS: A total of 360 patients with atrial fibrillation (AF) undergoing oral anticoagulant (ACo) therapy, with a target INR of 2.0-3.5, were followed prospectively for a period of 48 ± 7.2 months. The patients were evaluated on average every 30 days and were investigated regarding the presence of associated pathology that could lead to bleeding. RESULTS: A total of 338 patients participated in the present study. Of these, 210 (62.13%) were females. Mitral stenosis was present in 218 patients (64.4%), a mitral biological prosthesis in 64 (18.9%) and mitral valve failure in 56 (16.5%) patients. Bleeding occurred in 65 patients (19.2%), being severe in 7 (10%) patients. In 38/65 patients, a new associated disease was identified, which facilitated bleeding. An associated disease was identified in 100% of the patients with bleeding within the therapeutic range, against 49.05% of associated disease diagnosis in those with an INR < 3.5 (p=0.001). CONCLUSION: The diagnosis of a local disease associated to the bleeding was frequent among those patients undergoing oral anticoagulant therapy (58.5%). There was an association between bleeding with an INR within the therapeutic range (INR=2.0-3.5) and the diagnosis of a pathology predisposing to bleeding (p<0.001). It is mandatory to investigate the cause of bleeding in patients undergoing oral anticoagulant therapy, especially if the INR is within the therapeutic range. Hemorragia anticoagulantes estenosis de la válvula mitral fibrilación atrial estenose da valva mitral fibrilação atrial Hemorrhage anticoagulants mitral valve stenosis atrial fibrillation Diseases of the circulatory (Cardiovascular) system Guilherme Sobreira Spina verfasserin aut Roney Orismar Sampaio verfasserin aut Flávio Tarasoutchi verfasserin aut Max Grinberg verfasserin aut In Arquivos Brasileiros de Cardiologia Sociedade Brasileira de Cardiologia (SBC), 2004 93(2009), 2, Seite 174-179 (DE-627)320623572 (DE-600)2023015-1 16784170 nnns volume:93 year:2009 number:2 pages:174-179 https://doi.org/10.1590/S0066-782X2009000800017 kostenfrei https://doaj.org/article/ca8f6ab1cec04d42ada7d4d21ba88d7d kostenfrei http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2009000800017 kostenfrei https://doaj.org/toc/0066-782X Journal toc kostenfrei https://doaj.org/toc/1678-4170 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 93 2009 2 174-179 |
allfieldsSound |
10.1590/S0066-782X2009000800017 doi (DE-627)DOAJ027733734 (DE-599)DOAJca8f6ab1cec04d42ada7d4d21ba88d7d DE-627 ger DE-627 rakwb eng por RC666-701 Paulo de Lara Lavítola verfasserin aut Sangramento durante a anticoagulação oral: alerta sobre um mal maior Sangrado durante la anticoagulación oral: alerta sobre un mal mayor Bleeding during oral anticoagulant therapy: warning against a greater hazard 2009 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier FUNDAMENTO: Sangramento é uma das grandes preocupações em pacientes sob anticoagulação oral. OBJETIVO: Investigar causas determinantes do sangramento em usuários de anticoagulante oral. MÉTODOS: Foram acompanhados prospectivamente, por 48 ± 7,2 meses, 360 pacientes com fibrilação atrial (FA), todos em uso de anticoagulante oral (ACo) com INR-alvo de 2,0-3,5, avaliados em média a cada 30 dias. Os pacientes foram investigados quanto à presença de patologia associada que levasse a sangramento. RESULTADOS: Participaram deste estudo 338 pacientes. Desses, 210 (62,13%) eram do sexo feminino. A estenose mitral estava presente em 218 pacientes (64,4%), a prótese biológica mitral em 64 (18,9%) e a insuficiência da valva mitral em 56 (16,5%). O sangramento ocorreu em 65 pacientes (19,2%) e de forma grave em 7 (10%). Em 38/65 pacientes (58,5%), identificou-se nova doença associada, facilitadora do sangramento. Em 100% dos pacientes com sangramento na faixa terapêutica, foi encontrada doença associada, contra 49,05% de diagnóstico de doenças associadas naqueles com INR < 3,5 (p = 0,001). CONCLUSÃO: O diagnóstico de doença local associada ao sangramento foi frequente entre os medicados com anticoagulante oral (58,5%). Houve associação entre sangramento com INR na faixa terapêutica (INR 2,0-3,5) e diagnóstico de patologia predisponente a sangramento (p < 0,001). Em pacientes em uso de anticoagulante oral que apresentam sangramento, é mandatória a investigação da causa, sobretudo se a INR estiver na faixa terapêutica.<br<FUNDAMENTO: El sangrado es una de las grandes preocupaciones en pacientes bajo anticoagulación oral. OBJETIVO: Investigar causas determinantes del sangrado en usuarios de anticoagulante oral. MÉTODOS: Se realizó el seguimiento, prospectivamente, por 48 ± 7,2 meses, de 360 pacientes con fibrilación atrial (FA), todos en uso de anticoagulante oral (ACo) con INR-objetivo de 2,0-3,5, evaluados en promedio cada 30 días. Los pacientes se investigaron sobre la presencia de patología asociada que llevara al sangrado. RESULTADOS: Participaron en este estudio 338 pacientes. De ellos, 210 (62,13%) eran del sexo femenino. La estenosis mitral estaba presente en 218 pacientes (64,4%), la prótesis biológica mitral en 64 (18,9%) y la insuficiencia de la válvula mitral en 56 (16,5%). El sangrado ocurrió en 65 pacientes (19,2%) y de forma grave en 7 (10%). En 38/65 pacientes (58,5%), se identificó nueva enfermedad asociada, facilitadora del sangrado. En el 100% de los pacientes con sangrado en el intervalo terapéutico, se encontró enfermedad asociada, contra el 49,05% de diagnóstico de enfermedades asociadas en aquellos con INR < 3,5 (p = 0,001). CONCLUSIÓN: El diagnóstico de enfermedad local asociada al sangrado fue frecuente entre los medicados con anticoagulante oral (58,5%). Hubo asociación entre sangrado con INR en el intervalo terapéutico (INR 2,0-3,5) y diagnóstico de patología predisponente a sangrado (p < 0,001). En pacientes en uso de anticoagulante oral que presentan sangrado, es indispensable la investigación de la causa, sobre todo si la INR está en el intervalo terapéutico.<br<BACKGROUND: Bleeding is one of the main concerns in patients undergoing oral anticoagulation therapy. OBJECTIVE: To investigate the determinant causes of bleeding in patients undergoing oral anticoagulant therapy. METHODS: A total of 360 patients with atrial fibrillation (AF) undergoing oral anticoagulant (ACo) therapy, with a target INR of 2.0-3.5, were followed prospectively for a period of 48 ± 7.2 months. The patients were evaluated on average every 30 days and were investigated regarding the presence of associated pathology that could lead to bleeding. RESULTS: A total of 338 patients participated in the present study. Of these, 210 (62.13%) were females. Mitral stenosis was present in 218 patients (64.4%), a mitral biological prosthesis in 64 (18.9%) and mitral valve failure in 56 (16.5%) patients. Bleeding occurred in 65 patients (19.2%), being severe in 7 (10%) patients. In 38/65 patients, a new associated disease was identified, which facilitated bleeding. An associated disease was identified in 100% of the patients with bleeding within the therapeutic range, against 49.05% of associated disease diagnosis in those with an INR < 3.5 (p=0.001). CONCLUSION: The diagnosis of a local disease associated to the bleeding was frequent among those patients undergoing oral anticoagulant therapy (58.5%). There was an association between bleeding with an INR within the therapeutic range (INR=2.0-3.5) and the diagnosis of a pathology predisposing to bleeding (p<0.001). It is mandatory to investigate the cause of bleeding in patients undergoing oral anticoagulant therapy, especially if the INR is within the therapeutic range. Hemorragia anticoagulantes estenosis de la válvula mitral fibrilación atrial estenose da valva mitral fibrilação atrial Hemorrhage anticoagulants mitral valve stenosis atrial fibrillation Diseases of the circulatory (Cardiovascular) system Guilherme Sobreira Spina verfasserin aut Roney Orismar Sampaio verfasserin aut Flávio Tarasoutchi verfasserin aut Max Grinberg verfasserin aut In Arquivos Brasileiros de Cardiologia Sociedade Brasileira de Cardiologia (SBC), 2004 93(2009), 2, Seite 174-179 (DE-627)320623572 (DE-600)2023015-1 16784170 nnns volume:93 year:2009 number:2 pages:174-179 https://doi.org/10.1590/S0066-782X2009000800017 kostenfrei https://doaj.org/article/ca8f6ab1cec04d42ada7d4d21ba88d7d kostenfrei http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2009000800017 kostenfrei https://doaj.org/toc/0066-782X Journal toc kostenfrei https://doaj.org/toc/1678-4170 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 93 2009 2 174-179 |
language |
English Portuguese |
source |
In Arquivos Brasileiros de Cardiologia 93(2009), 2, Seite 174-179 volume:93 year:2009 number:2 pages:174-179 |
sourceStr |
In Arquivos Brasileiros de Cardiologia 93(2009), 2, Seite 174-179 volume:93 year:2009 number:2 pages:174-179 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
Hemorragia anticoagulantes estenosis de la válvula mitral fibrilación atrial estenose da valva mitral fibrilação atrial Hemorrhage anticoagulants mitral valve stenosis atrial fibrillation Diseases of the circulatory (Cardiovascular) system |
isfreeaccess_bool |
true |
container_title |
Arquivos Brasileiros de Cardiologia |
authorswithroles_txt_mv |
Paulo de Lara Lavítola @@aut@@ Guilherme Sobreira Spina @@aut@@ Roney Orismar Sampaio @@aut@@ Flávio Tarasoutchi @@aut@@ Max Grinberg @@aut@@ |
publishDateDaySort_date |
2009-01-01T00:00:00Z |
hierarchy_top_id |
320623572 |
id |
DOAJ027733734 |
language_de |
englisch portugiesisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ027733734</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230307120523.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2009 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1590/S0066-782X2009000800017</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ027733734</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJca8f6ab1cec04d42ada7d4d21ba88d7d</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield><subfield code="a">por</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC666-701</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Paulo de Lara Lavítola</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Sangramento durante a anticoagulação oral: alerta sobre um mal maior Sangrado durante la anticoagulación oral: alerta sobre un mal mayor Bleeding during oral anticoagulant therapy: warning against a greater hazard</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2009</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">FUNDAMENTO: Sangramento é uma das grandes preocupações em pacientes sob anticoagulação oral. OBJETIVO: Investigar causas determinantes do sangramento em usuários de anticoagulante oral. MÉTODOS: Foram acompanhados prospectivamente, por 48 ± 7,2 meses, 360 pacientes com fibrilação atrial (FA), todos em uso de anticoagulante oral (ACo) com INR-alvo de 2,0-3,5, avaliados em média a cada 30 dias. Os pacientes foram investigados quanto à presença de patologia associada que levasse a sangramento. RESULTADOS: Participaram deste estudo 338 pacientes. Desses, 210 (62,13%) eram do sexo feminino. A estenose mitral estava presente em 218 pacientes (64,4%), a prótese biológica mitral em 64 (18,9%) e a insuficiência da valva mitral em 56 (16,5%). O sangramento ocorreu em 65 pacientes (19,2%) e de forma grave em 7 (10%). Em 38/65 pacientes (58,5%), identificou-se nova doença associada, facilitadora do sangramento. Em 100% dos pacientes com sangramento na faixa terapêutica, foi encontrada doença associada, contra 49,05% de diagnóstico de doenças associadas naqueles com INR < 3,5 (p = 0,001). CONCLUSÃO: O diagnóstico de doença local associada ao sangramento foi frequente entre os medicados com anticoagulante oral (58,5%). Houve associação entre sangramento com INR na faixa terapêutica (INR 2,0-3,5) e diagnóstico de patologia predisponente a sangramento (p < 0,001). Em pacientes em uso de anticoagulante oral que apresentam sangramento, é mandatória a investigação da causa, sobretudo se a INR estiver na faixa terapêutica.<br<FUNDAMENTO: El sangrado es una de las grandes preocupaciones en pacientes bajo anticoagulación oral. OBJETIVO: Investigar causas determinantes del sangrado en usuarios de anticoagulante oral. MÉTODOS: Se realizó el seguimiento, prospectivamente, por 48 ± 7,2 meses, de 360 pacientes con fibrilación atrial (FA), todos en uso de anticoagulante oral (ACo) con INR-objetivo de 2,0-3,5, evaluados en promedio cada 30 días. Los pacientes se investigaron sobre la presencia de patología asociada que llevara al sangrado. RESULTADOS: Participaron en este estudio 338 pacientes. De ellos, 210 (62,13%) eran del sexo femenino. La estenosis mitral estaba presente en 218 pacientes (64,4%), la prótesis biológica mitral en 64 (18,9%) y la insuficiencia de la válvula mitral en 56 (16,5%). El sangrado ocurrió en 65 pacientes (19,2%) y de forma grave en 7 (10%). En 38/65 pacientes (58,5%), se identificó nueva enfermedad asociada, facilitadora del sangrado. En el 100% de los pacientes con sangrado en el intervalo terapéutico, se encontró enfermedad asociada, contra el 49,05% de diagnóstico de enfermedades asociadas en aquellos con INR < 3,5 (p = 0,001). CONCLUSIÓN: El diagnóstico de enfermedad local asociada al sangrado fue frecuente entre los medicados con anticoagulante oral (58,5%). Hubo asociación entre sangrado con INR en el intervalo terapéutico (INR 2,0-3,5) y diagnóstico de patología predisponente a sangrado (p < 0,001). En pacientes en uso de anticoagulante oral que presentan sangrado, es indispensable la investigación de la causa, sobre todo si la INR está en el intervalo terapéutico.<br<BACKGROUND: Bleeding is one of the main concerns in patients undergoing oral anticoagulation therapy. OBJECTIVE: To investigate the determinant causes of bleeding in patients undergoing oral anticoagulant therapy. METHODS: A total of 360 patients with atrial fibrillation (AF) undergoing oral anticoagulant (ACo) therapy, with a target INR of 2.0-3.5, were followed prospectively for a period of 48 ± 7.2 months. The patients were evaluated on average every 30 days and were investigated regarding the presence of associated pathology that could lead to bleeding. RESULTS: A total of 338 patients participated in the present study. Of these, 210 (62.13%) were females. Mitral stenosis was present in 218 patients (64.4%), a mitral biological prosthesis in 64 (18.9%) and mitral valve failure in 56 (16.5%) patients. Bleeding occurred in 65 patients (19.2%), being severe in 7 (10%) patients. In 38/65 patients, a new associated disease was identified, which facilitated bleeding. An associated disease was identified in 100% of the patients with bleeding within the therapeutic range, against 49.05% of associated disease diagnosis in those with an INR < 3.5 (p=0.001). CONCLUSION: The diagnosis of a local disease associated to the bleeding was frequent among those patients undergoing oral anticoagulant therapy (58.5%). There was an association between bleeding with an INR within the therapeutic range (INR=2.0-3.5) and the diagnosis of a pathology predisposing to bleeding (p<0.001). It is mandatory to investigate the cause of bleeding in patients undergoing oral anticoagulant therapy, especially if the INR is within the therapeutic range.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hemorragia</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">anticoagulantes</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">estenosis de la válvula mitral</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">fibrilación atrial</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">estenose da valva mitral</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">fibrilação atrial</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hemorrhage</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">anticoagulants</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">mitral valve stenosis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">atrial fibrillation</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the circulatory (Cardiovascular) system</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Guilherme Sobreira Spina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Roney Orismar Sampaio</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Flávio Tarasoutchi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Max Grinberg</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Arquivos Brasileiros de Cardiologia</subfield><subfield code="d">Sociedade Brasileira de Cardiologia (SBC), 2004</subfield><subfield code="g">93(2009), 2, Seite 174-179</subfield><subfield code="w">(DE-627)320623572</subfield><subfield code="w">(DE-600)2023015-1</subfield><subfield code="x">16784170</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:93</subfield><subfield code="g">year:2009</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:174-179</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1590/S0066-782X2009000800017</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/ca8f6ab1cec04d42ada7d4d21ba88d7d</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2009000800017</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/0066-782X</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1678-4170</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">93</subfield><subfield code="j">2009</subfield><subfield code="e">2</subfield><subfield code="h">174-179</subfield></datafield></record></collection>
|
callnumber-first |
R - Medicine |
author |
Paulo de Lara Lavítola |
spellingShingle |
Paulo de Lara Lavítola misc RC666-701 misc Hemorragia misc anticoagulantes misc estenosis de la válvula mitral misc fibrilación atrial misc estenose da valva mitral misc fibrilação atrial misc Hemorrhage misc anticoagulants misc mitral valve stenosis misc atrial fibrillation misc Diseases of the circulatory (Cardiovascular) system Sangramento durante a anticoagulação oral: alerta sobre um mal maior Sangrado durante la anticoagulación oral: alerta sobre un mal mayor Bleeding during oral anticoagulant therapy: warning against a greater hazard |
authorStr |
Paulo de Lara Lavítola |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)320623572 |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut aut aut aut |
collection |
DOAJ |
remote_str |
true |
callnumber-label |
RC666-701 |
illustrated |
Not Illustrated |
issn |
16784170 |
topic_title |
RC666-701 Sangramento durante a anticoagulação oral: alerta sobre um mal maior Sangrado durante la anticoagulación oral: alerta sobre un mal mayor Bleeding during oral anticoagulant therapy: warning against a greater hazard Hemorragia anticoagulantes estenosis de la válvula mitral fibrilación atrial estenose da valva mitral fibrilação atrial Hemorrhage anticoagulants mitral valve stenosis atrial fibrillation |
topic |
misc RC666-701 misc Hemorragia misc anticoagulantes misc estenosis de la válvula mitral misc fibrilación atrial misc estenose da valva mitral misc fibrilação atrial misc Hemorrhage misc anticoagulants misc mitral valve stenosis misc atrial fibrillation misc Diseases of the circulatory (Cardiovascular) system |
topic_unstemmed |
misc RC666-701 misc Hemorragia misc anticoagulantes misc estenosis de la válvula mitral misc fibrilación atrial misc estenose da valva mitral misc fibrilação atrial misc Hemorrhage misc anticoagulants misc mitral valve stenosis misc atrial fibrillation misc Diseases of the circulatory (Cardiovascular) system |
topic_browse |
misc RC666-701 misc Hemorragia misc anticoagulantes misc estenosis de la válvula mitral misc fibrilación atrial misc estenose da valva mitral misc fibrilação atrial misc Hemorrhage misc anticoagulants misc mitral valve stenosis misc atrial fibrillation misc Diseases of the circulatory (Cardiovascular) system |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Arquivos Brasileiros de Cardiologia |
hierarchy_parent_id |
320623572 |
hierarchy_top_title |
Arquivos Brasileiros de Cardiologia |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)320623572 (DE-600)2023015-1 |
title |
Sangramento durante a anticoagulação oral: alerta sobre um mal maior Sangrado durante la anticoagulación oral: alerta sobre un mal mayor Bleeding during oral anticoagulant therapy: warning against a greater hazard |
ctrlnum |
(DE-627)DOAJ027733734 (DE-599)DOAJca8f6ab1cec04d42ada7d4d21ba88d7d |
title_full |
Sangramento durante a anticoagulação oral: alerta sobre um mal maior Sangrado durante la anticoagulación oral: alerta sobre un mal mayor Bleeding during oral anticoagulant therapy: warning against a greater hazard |
author_sort |
Paulo de Lara Lavítola |
journal |
Arquivos Brasileiros de Cardiologia |
journalStr |
Arquivos Brasileiros de Cardiologia |
callnumber-first-code |
R |
lang_code |
eng por |
isOA_bool |
true |
recordtype |
marc |
publishDateSort |
2009 |
contenttype_str_mv |
txt |
container_start_page |
174 |
author_browse |
Paulo de Lara Lavítola Guilherme Sobreira Spina Roney Orismar Sampaio Flávio Tarasoutchi Max Grinberg |
container_volume |
93 |
class |
RC666-701 |
format_se |
Elektronische Aufsätze |
author-letter |
Paulo de Lara Lavítola |
doi_str_mv |
10.1590/S0066-782X2009000800017 |
author2-role |
verfasserin |
title_sort |
sangramento durante a anticoagulação oral: alerta sobre um mal maior sangrado durante la anticoagulación oral: alerta sobre un mal mayor bleeding during oral anticoagulant therapy: warning against a greater hazard |
callnumber |
RC666-701 |
title_auth |
Sangramento durante a anticoagulação oral: alerta sobre um mal maior Sangrado durante la anticoagulación oral: alerta sobre un mal mayor Bleeding during oral anticoagulant therapy: warning against a greater hazard |
abstract |
FUNDAMENTO: Sangramento é uma das grandes preocupações em pacientes sob anticoagulação oral. OBJETIVO: Investigar causas determinantes do sangramento em usuários de anticoagulante oral. MÉTODOS: Foram acompanhados prospectivamente, por 48 ± 7,2 meses, 360 pacientes com fibrilação atrial (FA), todos em uso de anticoagulante oral (ACo) com INR-alvo de 2,0-3,5, avaliados em média a cada 30 dias. Os pacientes foram investigados quanto à presença de patologia associada que levasse a sangramento. RESULTADOS: Participaram deste estudo 338 pacientes. Desses, 210 (62,13%) eram do sexo feminino. A estenose mitral estava presente em 218 pacientes (64,4%), a prótese biológica mitral em 64 (18,9%) e a insuficiência da valva mitral em 56 (16,5%). O sangramento ocorreu em 65 pacientes (19,2%) e de forma grave em 7 (10%). Em 38/65 pacientes (58,5%), identificou-se nova doença associada, facilitadora do sangramento. Em 100% dos pacientes com sangramento na faixa terapêutica, foi encontrada doença associada, contra 49,05% de diagnóstico de doenças associadas naqueles com INR < 3,5 (p = 0,001). CONCLUSÃO: O diagnóstico de doença local associada ao sangramento foi frequente entre os medicados com anticoagulante oral (58,5%). Houve associação entre sangramento com INR na faixa terapêutica (INR 2,0-3,5) e diagnóstico de patologia predisponente a sangramento (p < 0,001). Em pacientes em uso de anticoagulante oral que apresentam sangramento, é mandatória a investigação da causa, sobretudo se a INR estiver na faixa terapêutica.<br<FUNDAMENTO: El sangrado es una de las grandes preocupaciones en pacientes bajo anticoagulación oral. OBJETIVO: Investigar causas determinantes del sangrado en usuarios de anticoagulante oral. MÉTODOS: Se realizó el seguimiento, prospectivamente, por 48 ± 7,2 meses, de 360 pacientes con fibrilación atrial (FA), todos en uso de anticoagulante oral (ACo) con INR-objetivo de 2,0-3,5, evaluados en promedio cada 30 días. Los pacientes se investigaron sobre la presencia de patología asociada que llevara al sangrado. RESULTADOS: Participaron en este estudio 338 pacientes. De ellos, 210 (62,13%) eran del sexo femenino. La estenosis mitral estaba presente en 218 pacientes (64,4%), la prótesis biológica mitral en 64 (18,9%) y la insuficiencia de la válvula mitral en 56 (16,5%). El sangrado ocurrió en 65 pacientes (19,2%) y de forma grave en 7 (10%). En 38/65 pacientes (58,5%), se identificó nueva enfermedad asociada, facilitadora del sangrado. En el 100% de los pacientes con sangrado en el intervalo terapéutico, se encontró enfermedad asociada, contra el 49,05% de diagnóstico de enfermedades asociadas en aquellos con INR < 3,5 (p = 0,001). CONCLUSIÓN: El diagnóstico de enfermedad local asociada al sangrado fue frecuente entre los medicados con anticoagulante oral (58,5%). Hubo asociación entre sangrado con INR en el intervalo terapéutico (INR 2,0-3,5) y diagnóstico de patología predisponente a sangrado (p < 0,001). En pacientes en uso de anticoagulante oral que presentan sangrado, es indispensable la investigación de la causa, sobre todo si la INR está en el intervalo terapéutico.<br<BACKGROUND: Bleeding is one of the main concerns in patients undergoing oral anticoagulation therapy. OBJECTIVE: To investigate the determinant causes of bleeding in patients undergoing oral anticoagulant therapy. METHODS: A total of 360 patients with atrial fibrillation (AF) undergoing oral anticoagulant (ACo) therapy, with a target INR of 2.0-3.5, were followed prospectively for a period of 48 ± 7.2 months. The patients were evaluated on average every 30 days and were investigated regarding the presence of associated pathology that could lead to bleeding. RESULTS: A total of 338 patients participated in the present study. Of these, 210 (62.13%) were females. Mitral stenosis was present in 218 patients (64.4%), a mitral biological prosthesis in 64 (18.9%) and mitral valve failure in 56 (16.5%) patients. Bleeding occurred in 65 patients (19.2%), being severe in 7 (10%) patients. In 38/65 patients, a new associated disease was identified, which facilitated bleeding. An associated disease was identified in 100% of the patients with bleeding within the therapeutic range, against 49.05% of associated disease diagnosis in those with an INR < 3.5 (p=0.001). CONCLUSION: The diagnosis of a local disease associated to the bleeding was frequent among those patients undergoing oral anticoagulant therapy (58.5%). There was an association between bleeding with an INR within the therapeutic range (INR=2.0-3.5) and the diagnosis of a pathology predisposing to bleeding (p<0.001). It is mandatory to investigate the cause of bleeding in patients undergoing oral anticoagulant therapy, especially if the INR is within the therapeutic range. |
abstractGer |
FUNDAMENTO: Sangramento é uma das grandes preocupações em pacientes sob anticoagulação oral. OBJETIVO: Investigar causas determinantes do sangramento em usuários de anticoagulante oral. MÉTODOS: Foram acompanhados prospectivamente, por 48 ± 7,2 meses, 360 pacientes com fibrilação atrial (FA), todos em uso de anticoagulante oral (ACo) com INR-alvo de 2,0-3,5, avaliados em média a cada 30 dias. Os pacientes foram investigados quanto à presença de patologia associada que levasse a sangramento. RESULTADOS: Participaram deste estudo 338 pacientes. Desses, 210 (62,13%) eram do sexo feminino. A estenose mitral estava presente em 218 pacientes (64,4%), a prótese biológica mitral em 64 (18,9%) e a insuficiência da valva mitral em 56 (16,5%). O sangramento ocorreu em 65 pacientes (19,2%) e de forma grave em 7 (10%). Em 38/65 pacientes (58,5%), identificou-se nova doença associada, facilitadora do sangramento. Em 100% dos pacientes com sangramento na faixa terapêutica, foi encontrada doença associada, contra 49,05% de diagnóstico de doenças associadas naqueles com INR < 3,5 (p = 0,001). CONCLUSÃO: O diagnóstico de doença local associada ao sangramento foi frequente entre os medicados com anticoagulante oral (58,5%). Houve associação entre sangramento com INR na faixa terapêutica (INR 2,0-3,5) e diagnóstico de patologia predisponente a sangramento (p < 0,001). Em pacientes em uso de anticoagulante oral que apresentam sangramento, é mandatória a investigação da causa, sobretudo se a INR estiver na faixa terapêutica.<br<FUNDAMENTO: El sangrado es una de las grandes preocupaciones en pacientes bajo anticoagulación oral. OBJETIVO: Investigar causas determinantes del sangrado en usuarios de anticoagulante oral. MÉTODOS: Se realizó el seguimiento, prospectivamente, por 48 ± 7,2 meses, de 360 pacientes con fibrilación atrial (FA), todos en uso de anticoagulante oral (ACo) con INR-objetivo de 2,0-3,5, evaluados en promedio cada 30 días. Los pacientes se investigaron sobre la presencia de patología asociada que llevara al sangrado. RESULTADOS: Participaron en este estudio 338 pacientes. De ellos, 210 (62,13%) eran del sexo femenino. La estenosis mitral estaba presente en 218 pacientes (64,4%), la prótesis biológica mitral en 64 (18,9%) y la insuficiencia de la válvula mitral en 56 (16,5%). El sangrado ocurrió en 65 pacientes (19,2%) y de forma grave en 7 (10%). En 38/65 pacientes (58,5%), se identificó nueva enfermedad asociada, facilitadora del sangrado. En el 100% de los pacientes con sangrado en el intervalo terapéutico, se encontró enfermedad asociada, contra el 49,05% de diagnóstico de enfermedades asociadas en aquellos con INR < 3,5 (p = 0,001). CONCLUSIÓN: El diagnóstico de enfermedad local asociada al sangrado fue frecuente entre los medicados con anticoagulante oral (58,5%). Hubo asociación entre sangrado con INR en el intervalo terapéutico (INR 2,0-3,5) y diagnóstico de patología predisponente a sangrado (p < 0,001). En pacientes en uso de anticoagulante oral que presentan sangrado, es indispensable la investigación de la causa, sobre todo si la INR está en el intervalo terapéutico.<br<BACKGROUND: Bleeding is one of the main concerns in patients undergoing oral anticoagulation therapy. OBJECTIVE: To investigate the determinant causes of bleeding in patients undergoing oral anticoagulant therapy. METHODS: A total of 360 patients with atrial fibrillation (AF) undergoing oral anticoagulant (ACo) therapy, with a target INR of 2.0-3.5, were followed prospectively for a period of 48 ± 7.2 months. The patients were evaluated on average every 30 days and were investigated regarding the presence of associated pathology that could lead to bleeding. RESULTS: A total of 338 patients participated in the present study. Of these, 210 (62.13%) were females. Mitral stenosis was present in 218 patients (64.4%), a mitral biological prosthesis in 64 (18.9%) and mitral valve failure in 56 (16.5%) patients. Bleeding occurred in 65 patients (19.2%), being severe in 7 (10%) patients. In 38/65 patients, a new associated disease was identified, which facilitated bleeding. An associated disease was identified in 100% of the patients with bleeding within the therapeutic range, against 49.05% of associated disease diagnosis in those with an INR < 3.5 (p=0.001). CONCLUSION: The diagnosis of a local disease associated to the bleeding was frequent among those patients undergoing oral anticoagulant therapy (58.5%). There was an association between bleeding with an INR within the therapeutic range (INR=2.0-3.5) and the diagnosis of a pathology predisposing to bleeding (p<0.001). It is mandatory to investigate the cause of bleeding in patients undergoing oral anticoagulant therapy, especially if the INR is within the therapeutic range. |
abstract_unstemmed |
FUNDAMENTO: Sangramento é uma das grandes preocupações em pacientes sob anticoagulação oral. OBJETIVO: Investigar causas determinantes do sangramento em usuários de anticoagulante oral. MÉTODOS: Foram acompanhados prospectivamente, por 48 ± 7,2 meses, 360 pacientes com fibrilação atrial (FA), todos em uso de anticoagulante oral (ACo) com INR-alvo de 2,0-3,5, avaliados em média a cada 30 dias. Os pacientes foram investigados quanto à presença de patologia associada que levasse a sangramento. RESULTADOS: Participaram deste estudo 338 pacientes. Desses, 210 (62,13%) eram do sexo feminino. A estenose mitral estava presente em 218 pacientes (64,4%), a prótese biológica mitral em 64 (18,9%) e a insuficiência da valva mitral em 56 (16,5%). O sangramento ocorreu em 65 pacientes (19,2%) e de forma grave em 7 (10%). Em 38/65 pacientes (58,5%), identificou-se nova doença associada, facilitadora do sangramento. Em 100% dos pacientes com sangramento na faixa terapêutica, foi encontrada doença associada, contra 49,05% de diagnóstico de doenças associadas naqueles com INR < 3,5 (p = 0,001). CONCLUSÃO: O diagnóstico de doença local associada ao sangramento foi frequente entre os medicados com anticoagulante oral (58,5%). Houve associação entre sangramento com INR na faixa terapêutica (INR 2,0-3,5) e diagnóstico de patologia predisponente a sangramento (p < 0,001). Em pacientes em uso de anticoagulante oral que apresentam sangramento, é mandatória a investigação da causa, sobretudo se a INR estiver na faixa terapêutica.<br<FUNDAMENTO: El sangrado es una de las grandes preocupaciones en pacientes bajo anticoagulación oral. OBJETIVO: Investigar causas determinantes del sangrado en usuarios de anticoagulante oral. MÉTODOS: Se realizó el seguimiento, prospectivamente, por 48 ± 7,2 meses, de 360 pacientes con fibrilación atrial (FA), todos en uso de anticoagulante oral (ACo) con INR-objetivo de 2,0-3,5, evaluados en promedio cada 30 días. Los pacientes se investigaron sobre la presencia de patología asociada que llevara al sangrado. RESULTADOS: Participaron en este estudio 338 pacientes. De ellos, 210 (62,13%) eran del sexo femenino. La estenosis mitral estaba presente en 218 pacientes (64,4%), la prótesis biológica mitral en 64 (18,9%) y la insuficiencia de la válvula mitral en 56 (16,5%). El sangrado ocurrió en 65 pacientes (19,2%) y de forma grave en 7 (10%). En 38/65 pacientes (58,5%), se identificó nueva enfermedad asociada, facilitadora del sangrado. En el 100% de los pacientes con sangrado en el intervalo terapéutico, se encontró enfermedad asociada, contra el 49,05% de diagnóstico de enfermedades asociadas en aquellos con INR < 3,5 (p = 0,001). CONCLUSIÓN: El diagnóstico de enfermedad local asociada al sangrado fue frecuente entre los medicados con anticoagulante oral (58,5%). Hubo asociación entre sangrado con INR en el intervalo terapéutico (INR 2,0-3,5) y diagnóstico de patología predisponente a sangrado (p < 0,001). En pacientes en uso de anticoagulante oral que presentan sangrado, es indispensable la investigación de la causa, sobre todo si la INR está en el intervalo terapéutico.<br<BACKGROUND: Bleeding is one of the main concerns in patients undergoing oral anticoagulation therapy. OBJECTIVE: To investigate the determinant causes of bleeding in patients undergoing oral anticoagulant therapy. METHODS: A total of 360 patients with atrial fibrillation (AF) undergoing oral anticoagulant (ACo) therapy, with a target INR of 2.0-3.5, were followed prospectively for a period of 48 ± 7.2 months. The patients were evaluated on average every 30 days and were investigated regarding the presence of associated pathology that could lead to bleeding. RESULTS: A total of 338 patients participated in the present study. Of these, 210 (62.13%) were females. Mitral stenosis was present in 218 patients (64.4%), a mitral biological prosthesis in 64 (18.9%) and mitral valve failure in 56 (16.5%) patients. Bleeding occurred in 65 patients (19.2%), being severe in 7 (10%) patients. In 38/65 patients, a new associated disease was identified, which facilitated bleeding. An associated disease was identified in 100% of the patients with bleeding within the therapeutic range, against 49.05% of associated disease diagnosis in those with an INR < 3.5 (p=0.001). CONCLUSION: The diagnosis of a local disease associated to the bleeding was frequent among those patients undergoing oral anticoagulant therapy (58.5%). There was an association between bleeding with an INR within the therapeutic range (INR=2.0-3.5) and the diagnosis of a pathology predisposing to bleeding (p<0.001). It is mandatory to investigate the cause of bleeding in patients undergoing oral anticoagulant therapy, especially if the INR is within the therapeutic range. |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
container_issue |
2 |
title_short |
Sangramento durante a anticoagulação oral: alerta sobre um mal maior Sangrado durante la anticoagulación oral: alerta sobre un mal mayor Bleeding during oral anticoagulant therapy: warning against a greater hazard |
url |
https://doi.org/10.1590/S0066-782X2009000800017 https://doaj.org/article/ca8f6ab1cec04d42ada7d4d21ba88d7d http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2009000800017 https://doaj.org/toc/0066-782X https://doaj.org/toc/1678-4170 |
remote_bool |
true |
author2 |
Guilherme Sobreira Spina Roney Orismar Sampaio Flávio Tarasoutchi Max Grinberg |
author2Str |
Guilherme Sobreira Spina Roney Orismar Sampaio Flávio Tarasoutchi Max Grinberg |
ppnlink |
320623572 |
callnumber-subject |
RC - Internal Medicine |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
doi_str |
10.1590/S0066-782X2009000800017 |
callnumber-a |
RC666-701 |
up_date |
2024-07-03T13:45:09.258Z |
_version_ |
1803565724349759489 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ027733734</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230307120523.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2009 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1590/S0066-782X2009000800017</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ027733734</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJca8f6ab1cec04d42ada7d4d21ba88d7d</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield><subfield code="a">por</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC666-701</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Paulo de Lara Lavítola</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Sangramento durante a anticoagulação oral: alerta sobre um mal maior Sangrado durante la anticoagulación oral: alerta sobre un mal mayor Bleeding during oral anticoagulant therapy: warning against a greater hazard</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2009</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">FUNDAMENTO: Sangramento é uma das grandes preocupações em pacientes sob anticoagulação oral. OBJETIVO: Investigar causas determinantes do sangramento em usuários de anticoagulante oral. MÉTODOS: Foram acompanhados prospectivamente, por 48 ± 7,2 meses, 360 pacientes com fibrilação atrial (FA), todos em uso de anticoagulante oral (ACo) com INR-alvo de 2,0-3,5, avaliados em média a cada 30 dias. Os pacientes foram investigados quanto à presença de patologia associada que levasse a sangramento. RESULTADOS: Participaram deste estudo 338 pacientes. Desses, 210 (62,13%) eram do sexo feminino. A estenose mitral estava presente em 218 pacientes (64,4%), a prótese biológica mitral em 64 (18,9%) e a insuficiência da valva mitral em 56 (16,5%). O sangramento ocorreu em 65 pacientes (19,2%) e de forma grave em 7 (10%). Em 38/65 pacientes (58,5%), identificou-se nova doença associada, facilitadora do sangramento. Em 100% dos pacientes com sangramento na faixa terapêutica, foi encontrada doença associada, contra 49,05% de diagnóstico de doenças associadas naqueles com INR < 3,5 (p = 0,001). CONCLUSÃO: O diagnóstico de doença local associada ao sangramento foi frequente entre os medicados com anticoagulante oral (58,5%). Houve associação entre sangramento com INR na faixa terapêutica (INR 2,0-3,5) e diagnóstico de patologia predisponente a sangramento (p < 0,001). Em pacientes em uso de anticoagulante oral que apresentam sangramento, é mandatória a investigação da causa, sobretudo se a INR estiver na faixa terapêutica.<br<FUNDAMENTO: El sangrado es una de las grandes preocupaciones en pacientes bajo anticoagulación oral. OBJETIVO: Investigar causas determinantes del sangrado en usuarios de anticoagulante oral. MÉTODOS: Se realizó el seguimiento, prospectivamente, por 48 ± 7,2 meses, de 360 pacientes con fibrilación atrial (FA), todos en uso de anticoagulante oral (ACo) con INR-objetivo de 2,0-3,5, evaluados en promedio cada 30 días. Los pacientes se investigaron sobre la presencia de patología asociada que llevara al sangrado. RESULTADOS: Participaron en este estudio 338 pacientes. De ellos, 210 (62,13%) eran del sexo femenino. La estenosis mitral estaba presente en 218 pacientes (64,4%), la prótesis biológica mitral en 64 (18,9%) y la insuficiencia de la válvula mitral en 56 (16,5%). El sangrado ocurrió en 65 pacientes (19,2%) y de forma grave en 7 (10%). En 38/65 pacientes (58,5%), se identificó nueva enfermedad asociada, facilitadora del sangrado. En el 100% de los pacientes con sangrado en el intervalo terapéutico, se encontró enfermedad asociada, contra el 49,05% de diagnóstico de enfermedades asociadas en aquellos con INR < 3,5 (p = 0,001). CONCLUSIÓN: El diagnóstico de enfermedad local asociada al sangrado fue frecuente entre los medicados con anticoagulante oral (58,5%). Hubo asociación entre sangrado con INR en el intervalo terapéutico (INR 2,0-3,5) y diagnóstico de patología predisponente a sangrado (p < 0,001). En pacientes en uso de anticoagulante oral que presentan sangrado, es indispensable la investigación de la causa, sobre todo si la INR está en el intervalo terapéutico.<br<BACKGROUND: Bleeding is one of the main concerns in patients undergoing oral anticoagulation therapy. OBJECTIVE: To investigate the determinant causes of bleeding in patients undergoing oral anticoagulant therapy. METHODS: A total of 360 patients with atrial fibrillation (AF) undergoing oral anticoagulant (ACo) therapy, with a target INR of 2.0-3.5, were followed prospectively for a period of 48 ± 7.2 months. The patients were evaluated on average every 30 days and were investigated regarding the presence of associated pathology that could lead to bleeding. RESULTS: A total of 338 patients participated in the present study. Of these, 210 (62.13%) were females. Mitral stenosis was present in 218 patients (64.4%), a mitral biological prosthesis in 64 (18.9%) and mitral valve failure in 56 (16.5%) patients. Bleeding occurred in 65 patients (19.2%), being severe in 7 (10%) patients. In 38/65 patients, a new associated disease was identified, which facilitated bleeding. An associated disease was identified in 100% of the patients with bleeding within the therapeutic range, against 49.05% of associated disease diagnosis in those with an INR < 3.5 (p=0.001). CONCLUSION: The diagnosis of a local disease associated to the bleeding was frequent among those patients undergoing oral anticoagulant therapy (58.5%). There was an association between bleeding with an INR within the therapeutic range (INR=2.0-3.5) and the diagnosis of a pathology predisposing to bleeding (p<0.001). It is mandatory to investigate the cause of bleeding in patients undergoing oral anticoagulant therapy, especially if the INR is within the therapeutic range.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hemorragia</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">anticoagulantes</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">estenosis de la válvula mitral</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">fibrilación atrial</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">estenose da valva mitral</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">fibrilação atrial</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hemorrhage</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">anticoagulants</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">mitral valve stenosis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">atrial fibrillation</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the circulatory (Cardiovascular) system</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Guilherme Sobreira Spina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Roney Orismar Sampaio</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Flávio Tarasoutchi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Max Grinberg</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Arquivos Brasileiros de Cardiologia</subfield><subfield code="d">Sociedade Brasileira de Cardiologia (SBC), 2004</subfield><subfield code="g">93(2009), 2, Seite 174-179</subfield><subfield code="w">(DE-627)320623572</subfield><subfield code="w">(DE-600)2023015-1</subfield><subfield code="x">16784170</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:93</subfield><subfield code="g">year:2009</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:174-179</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1590/S0066-782X2009000800017</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/ca8f6ab1cec04d42ada7d4d21ba88d7d</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2009000800017</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/0066-782X</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1678-4170</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">93</subfield><subfield code="j">2009</subfield><subfield code="e">2</subfield><subfield code="h">174-179</subfield></datafield></record></collection>
|
score |
7.400098 |